PMCB - PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors
- PharmaCyte Biotech ( NASDAQ: PMCB ) said on Monday that it had signed a cooperation agreement with Iroquois Master Fund and its affiliates to includes two of Iroquois’ director designees to its Board of Directors.
- ( PMCB ) rose ~4% before the bell.
- Iroquois’ director designees, Jonathan Schechter and Joshua Silverman, will join PharmaCyte’s reconstituted Board as independent directors, the company said.
- "We are nearing the end of our process to fulfill the FDA’s requests to enable the clinical hold to be lifted. To date, approximately 90% of the FDA’s requests have been completed or are in process with one major pig study remaining to be completed," said PharmaCyte’s Chief Executive Officer, Kenneth Waggoner.
- Iroquois has agreed to certain customary standstill provisions and will support the Board’s full slate of directors at the 2022 Annual Meeting.
For further details see:
PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors